Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference
Corbus Pharmaceuticals (NASDAQ: CRBP) presented promising preclinical data for its novel oral cannabinoid, CRB-913, at the European Association for the Study of Diabetes 2022 Annual Conference. CRB-913, a CB1 inverse agonist, demonstrated significant anti-obesity effects by reducing body weight, fat content, and liver triglycerides in diet-induced obesity mouse models. Notably, CRB-913 enhanced the efficacy of incretin analogues such as liraglutide, semaglutide, and tirzepatide, suggesting a potential for combination therapy that could improve current obesity treatments.
- CRB-913 demonstrated significant weight and fat loss in preclinical models.
- Combination therapy with CRB-913 and incretin analogues showed enhanced efficacy.
- None.
- CRB-913 is a novel oral cannabinoid type 1 receptor (CB1) inverse agonist with potent pre-clinical anti-obesity activity
- CRB-913 markedly enhances pre-clinical efficacy of liraglutide, semaglutide, and tirzepatide
- CB1 inverse agonism is a clinically validated therapeutic approach to treating obesity
NORWOOD, Mass., Sept. 22, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced that preclinical data for CRB-913 are being presented today in an oral presentation at the European Association for the Study of Diabetes 2022 Annual Conference taking place in Stockholm, Sweden.
The data show that in the diet-induced obesity (DIO) mouse model, CRB-913 monotherapy demonstrated a reduction in body weight, body fat content, food consumption, liver triglycerides, and liver fat deposits as well as improvements in insulin resistance and leptinemia. Combining CRB-913 with the incretin analogues liraglutide, semaglutide, or tirzepatide demonstrated significant additive effects across all these outcomes.
"The data presented today are exciting as they demonstrate that CRB-913 is a differentiated CB1 inverse agonist with improved pharmacokinetic properties compared to the first generation of these drugs while still retaining the same efficacy," commented Rachael Brake, Ph.D., Chief Scientific Officer of Corbus. "Furthermore, potentially combining CRB-913 with an incretin analogue into a single therapy could meaningfully enhance the current standard of care as well as expand the number of patients who could benefit from anti-obesity drug therapy."
The EASD presentation is available on the company's website at: 58th European Association for the Study of Diabetes (EASD) presentation on CRB-913 (CB1 Inverse Agonist).
Corbus is an immunology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus' current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com and connect on Twitter, LinkedIn, and Facebook.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Corbus Investor Relations
Sean.moran@corbuspharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/corbus-presents-first-pre-clinical-data-for-crb-913-at-the-european-association-for-the-study-of-diabetes-2022-annual-conference-301630440.html
SOURCE Corbus Pharmaceuticals
FAQ
What is CRB-913 and its significance for obesity treatment?
What were the results of CRB-913's preclinical trials?
How does CRB-913 compare to existing obesity treatments?
What impact does CRB-913 have on current obesity drug therapies?
When was the data for CRB-913 presented?
